170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023

Background

The KRAS gene plays a crucial role in the development of pancreatic ductal adenocarcinoma (PDAC). This study aimed to investigate the frequency of KRAS mutations in patients with PDAC.

Methods

From 2020 to 2023, we retrospectively analyzed the KRAS status in 45 patients with PDAC. The distribution of clinical stages and the frequency of other mutations such as NRAS and BRCA2 were also evaluated.

Results

Among 45 patients, 30 (66.7%) had KRAS mutations, with the most frequent being G12D (50%), followed by G12V (26.6%). Q61K, G12A, A146T, G12R, and G12C mutations were less common. One patient with G12V mutation also had a BRCA2 mutation. In the mutated KRAS (mKRAS) group, 13 patients (43.3%) had metastatic disease, 12 (40%) had localized disease, and 5 (16.6%) had locally advanced disease. In the wild-type KRAS (wtKRAS) group, which consisted of 15 patients (33.3%), 7 (46.7%) had metastatic disease, 5 (33.3%) had localized disease, and 3 (20%) had locally advanced disease. One patient with wtKRAS also had a germline BRCA2 mutation. The distribution of clinical stages did not differ significantly between mKRAS and wtKRAS groups. NRAS mutation analysis was conducted in 41 patients, and no mutations were detected.

Conclusions

Our study revealed a high frequency of wtKRAS in patients with PDAC. Further investigation is needed to expound the clinical significance of KRAS status in this patient population.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.